NURS 6630 Final Exam (5 Versions, 300 Q & A, Latest-
2025/ 2026) / NURS 6630N Final Exam / NURS6630 Final
Exam / NURS6630N Final Exam: Walden University |
100% Verified and Correct Q & A |
Exam Format Overview
The NURS 6630 Final Exam (Psychopharmacologic Approaches to Treatment of
Psychopathology) consists of 75 questions per version, covering:
• Neurotransmission & Receptor Pharmacology
• Antipsychotics & Dopamine Receptor Occupancy
• ADHD Pharmacotherapy
• Mood Disorders & Antidepressants
• Anxiety, Sleep Disorders, & Insomnia
• Pain Management & Neuropathic Pain
• Substance Use Disorders
• Dementia & Alzheimer’s Disease
• Special Populations (Pediatrics, Geriatrics, Pregnancy)
VERSION 1: QUESTIONS & ANSWERS
Question 1:
What will the PMHNP most likely prescribe to a patient with psychotic aggression
who needs to manage the top-down cortical control and the excessive drive from
striatal hyperactivity?
A. Stimulants
,B. Antidepressants
C. Antipsychotics
D. SSRIs
Correct Answer-: C. Antipsychotics
Rationale: Antipsychotics are the primary treatment for psychotic aggression.
They manage both top-down cortical control (prefrontal cortex regulation) and
excessive drive from striatal hyperactivity (dopamine-mediated) by modulating
dopaminergic and serotonergic neurotransmission. Antipsychotics help regulate
the imbalance between cortical control and subcortical drive .
Question 2:
The PMHNP is selecting a medication treatment option for a patient who is
exhibiting psychotic behaviors with poor impulse control and aggression. Of the
available treatments, which can help temper some of the adverse effects or
symptoms that are normally caused by D2 antagonism?
A. First-generation, conventional antipsychotics
B. First-generation, atypical antipsychotics
C. Second-generation, conventional antipsychotics
D. Second-generation, atypical antipsychotics
Correct Answer-: D. Second-generation, atypical antipsychotics
Rationale: Second-generation (atypical) antipsychotics have a different receptor
binding profile than first-generation agents. They exhibit lower D2 receptor
affinity with higher serotonin 5-HT2A receptor antagonism, which helps temper
extrapyramidal symptoms (EPS) caused by D2 antagonism. The serotonin-
dopamine antagonism balance reduces the risk of motor side effects while
maintaining antipsychotic efficacy .
Question 3:
The PMHNP is discussing dopamine D2 receptor occupancy and its association
with aggressive behaviors in patients with the student. Why does the PMHNP
prescribe a standard dose of atypical antipsychotics?
,A. The doses are based on achieving 100% D2 receptor occupancy.
B. The doses are based on achieving a minimum of 80% D2 receptor occupancy.
C. The doses are based on achieving 60% D2 receptor occupancy.
D. None of the above.
Correct Answer-: C. The doses are based on achieving 60% D2 receptor
occupancy.
Rationale: Standard doses of atypical antipsychotics are designed to achieve
approximately 60% D2 receptor occupancy. This level provides therapeutic
efficacy for psychotic symptoms and aggression while minimizing extrapyramidal
side effects (EPS). Higher occupancy (>80%) is associated with increased risk of
EPS, while lower occupancy may be subtherapeutic. This 60% target represents
the optimal balance between efficacy and tolerability .
Question 4:
Why does the PMHNP avoid prescribing clozapine (Clozaril) as a first-line
treatment to the patient with psychosis and aggression?
A. There is too high a risk of serious adverse side effects.
B. It can exaggerate the psychotic symptoms.
C. Clozapine (Clozaril) should not be used as high-dose monotherapy.
D. There is no documentation that clozapine (Clozaril) is effective for patients who
are violent.
Correct Answer-: A. There is too high a risk of serious adverse side effects.
Rationale: Clozapine is reserved for treatment-resistant schizophrenia due to its
significant adverse effect profile, including agranulocytosis (requiring regular
absolute neutrophil count monitoring), myocarditis, seizures, and metabolic
syndrome. Due to these serious risks, it is not used as first-line therapy despite its
efficacy in refractory cases and aggression .
Question 5:
The PMHNP is caring for a patient on risperidone (Risperdal). Which action made
by the PMHNP exhibits proper care for this patient?
, A. Explaining to the patient that there are no risks of EPS
B. Prescribing the patient 12 mg/daily
C. Titrating the dose by increasing it every 5–7 days
D. Writing a prescription for a higher dose of oral risperidone (Risperdal) to
achieve high D2 receptor occupancy
Correct Answer-: C. Titrating the dose by increasing it every 5–7 days.
Rationale: Risperidone dosing should be titrated slowly, typically every 5–7 days,
to achieve therapeutic effect while minimizing adverse effects. This gradual
titration allows the patient to adjust to the medication and enables monitoring
for side effects such as extrapyramidal symptoms, orthostatic hypotension, and
sedation. Rapid titration increases the risk of adverse effects and non-adherence .
Question 6:
The PMHNP wants to prescribe Mr. Barber a mood stabilizer that will target
aggressive and impulsive symptoms by decreasing dopaminergic
neurotransmission. Which mood stabilizer will the PMHNP select?
A. Lithium (Lithane)
B. Phenytoin (Dilantin)
C. Valproate (Depakote)
D. Topiramate (Topamax)
Correct Answer-: C. Valproate (Depakote)
Rationale: Valproate (Depakote) decreases dopaminergic neurotransmission by
inhibiting dopamine release and increasing GABAergic activity, which helps
control impulsive and aggressive symptoms. Valproate is particularly effective in
treating bipolar disorder with mixed features and impulsivity. It is also used for
aggression associated with various psychiatric conditions .
Question 7:
The PMHNP is meeting with the parents of an 8-year-old patient who is receiving
an initial prescription for D-amphetamine. The PMHNP demonstrates appropriate
prescribing practices when she prescribes the following dose:
2025/ 2026) / NURS 6630N Final Exam / NURS6630 Final
Exam / NURS6630N Final Exam: Walden University |
100% Verified and Correct Q & A |
Exam Format Overview
The NURS 6630 Final Exam (Psychopharmacologic Approaches to Treatment of
Psychopathology) consists of 75 questions per version, covering:
• Neurotransmission & Receptor Pharmacology
• Antipsychotics & Dopamine Receptor Occupancy
• ADHD Pharmacotherapy
• Mood Disorders & Antidepressants
• Anxiety, Sleep Disorders, & Insomnia
• Pain Management & Neuropathic Pain
• Substance Use Disorders
• Dementia & Alzheimer’s Disease
• Special Populations (Pediatrics, Geriatrics, Pregnancy)
VERSION 1: QUESTIONS & ANSWERS
Question 1:
What will the PMHNP most likely prescribe to a patient with psychotic aggression
who needs to manage the top-down cortical control and the excessive drive from
striatal hyperactivity?
A. Stimulants
,B. Antidepressants
C. Antipsychotics
D. SSRIs
Correct Answer-: C. Antipsychotics
Rationale: Antipsychotics are the primary treatment for psychotic aggression.
They manage both top-down cortical control (prefrontal cortex regulation) and
excessive drive from striatal hyperactivity (dopamine-mediated) by modulating
dopaminergic and serotonergic neurotransmission. Antipsychotics help regulate
the imbalance between cortical control and subcortical drive .
Question 2:
The PMHNP is selecting a medication treatment option for a patient who is
exhibiting psychotic behaviors with poor impulse control and aggression. Of the
available treatments, which can help temper some of the adverse effects or
symptoms that are normally caused by D2 antagonism?
A. First-generation, conventional antipsychotics
B. First-generation, atypical antipsychotics
C. Second-generation, conventional antipsychotics
D. Second-generation, atypical antipsychotics
Correct Answer-: D. Second-generation, atypical antipsychotics
Rationale: Second-generation (atypical) antipsychotics have a different receptor
binding profile than first-generation agents. They exhibit lower D2 receptor
affinity with higher serotonin 5-HT2A receptor antagonism, which helps temper
extrapyramidal symptoms (EPS) caused by D2 antagonism. The serotonin-
dopamine antagonism balance reduces the risk of motor side effects while
maintaining antipsychotic efficacy .
Question 3:
The PMHNP is discussing dopamine D2 receptor occupancy and its association
with aggressive behaviors in patients with the student. Why does the PMHNP
prescribe a standard dose of atypical antipsychotics?
,A. The doses are based on achieving 100% D2 receptor occupancy.
B. The doses are based on achieving a minimum of 80% D2 receptor occupancy.
C. The doses are based on achieving 60% D2 receptor occupancy.
D. None of the above.
Correct Answer-: C. The doses are based on achieving 60% D2 receptor
occupancy.
Rationale: Standard doses of atypical antipsychotics are designed to achieve
approximately 60% D2 receptor occupancy. This level provides therapeutic
efficacy for psychotic symptoms and aggression while minimizing extrapyramidal
side effects (EPS). Higher occupancy (>80%) is associated with increased risk of
EPS, while lower occupancy may be subtherapeutic. This 60% target represents
the optimal balance between efficacy and tolerability .
Question 4:
Why does the PMHNP avoid prescribing clozapine (Clozaril) as a first-line
treatment to the patient with psychosis and aggression?
A. There is too high a risk of serious adverse side effects.
B. It can exaggerate the psychotic symptoms.
C. Clozapine (Clozaril) should not be used as high-dose monotherapy.
D. There is no documentation that clozapine (Clozaril) is effective for patients who
are violent.
Correct Answer-: A. There is too high a risk of serious adverse side effects.
Rationale: Clozapine is reserved for treatment-resistant schizophrenia due to its
significant adverse effect profile, including agranulocytosis (requiring regular
absolute neutrophil count monitoring), myocarditis, seizures, and metabolic
syndrome. Due to these serious risks, it is not used as first-line therapy despite its
efficacy in refractory cases and aggression .
Question 5:
The PMHNP is caring for a patient on risperidone (Risperdal). Which action made
by the PMHNP exhibits proper care for this patient?
, A. Explaining to the patient that there are no risks of EPS
B. Prescribing the patient 12 mg/daily
C. Titrating the dose by increasing it every 5–7 days
D. Writing a prescription for a higher dose of oral risperidone (Risperdal) to
achieve high D2 receptor occupancy
Correct Answer-: C. Titrating the dose by increasing it every 5–7 days.
Rationale: Risperidone dosing should be titrated slowly, typically every 5–7 days,
to achieve therapeutic effect while minimizing adverse effects. This gradual
titration allows the patient to adjust to the medication and enables monitoring
for side effects such as extrapyramidal symptoms, orthostatic hypotension, and
sedation. Rapid titration increases the risk of adverse effects and non-adherence .
Question 6:
The PMHNP wants to prescribe Mr. Barber a mood stabilizer that will target
aggressive and impulsive symptoms by decreasing dopaminergic
neurotransmission. Which mood stabilizer will the PMHNP select?
A. Lithium (Lithane)
B. Phenytoin (Dilantin)
C. Valproate (Depakote)
D. Topiramate (Topamax)
Correct Answer-: C. Valproate (Depakote)
Rationale: Valproate (Depakote) decreases dopaminergic neurotransmission by
inhibiting dopamine release and increasing GABAergic activity, which helps
control impulsive and aggressive symptoms. Valproate is particularly effective in
treating bipolar disorder with mixed features and impulsivity. It is also used for
aggression associated with various psychiatric conditions .
Question 7:
The PMHNP is meeting with the parents of an 8-year-old patient who is receiving
an initial prescription for D-amphetamine. The PMHNP demonstrates appropriate
prescribing practices when she prescribes the following dose:
